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E-mail address: Jerry.Shay@UTSouthwestern.edu (Differences between normal adult tissue stem cells and cancer stem/initiating cells remain poorly
deﬁned. For example, it is controversial if cancer stem cells can become fully quiescent, require a
stem cell niche, are better at repairing DNA damage than the bulk of the cancer cells, and if and
how they regulate symmetric versus asymmetric cell divisions. This minireview will not only pro-
vide our personal views to address some of these outstanding questions, but also present evidence
that an understanding of telomere dynamics and telomerase activity in normal and cancer stem
cells may provide additional insights into how tumors are initiated, and how they should be mon-
itored and treated.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction atively long telomeres compared to more differentiated somaticWhat do we really know about the differences between normal
tissue stem cells and cancer stem (initiating) cells? While this is a
complex question that covers many areas of previous and ongoing
research, this review will focus on comparing and contrasting the
role of telomeres and telomerase in normal and putative cancer
stem (initiating) cells. Understanding the dynamics of telomeres
and telomerase in normal and cancer stem cells may provide some
additional insights into deﬁning key differences between these cell
types. Since the discovery of rare tumor cells with stem cell-like
features, it has been proposed that these stem-like tumor cells
are the primary cellular component within a tumor that drives dis-
ease progression and metastasis. The alternative to the cancer stem
hypothesis is the clonal evolution hypothesis model that suggests
tumor progression results from genetic variability within the origi-
nal population of tumor cells that is permissive for more aggressive
subtypes. While the cancer stem cell hypothesis has been difﬁcult
to prove, as it makes few predictions, there are some common ele-
ments that are generally accepted. In addition to their ability to
self-renew and differentiate, cancer stem cells are also enriched
in cells postulated to be resistant to conventional radiation and
chemotherapy. While normal stem cells are chromosomally stable
containing a normal diploid genome, cancer stem cells are almost
always aneuploidy and have a signiﬁcant number of chromosomal
rearrangements. In addition, normal stem cells are generally quies-
cent or very slow growing, reside in a speciﬁc niche, and have rel-chemical Societies. Published by E
J.W. Shay).cells. In contrast, we ﬁnd cancer cells expressing stem cell markers
are not completely quiescent, and almost universally express can-
cer levels of telomerase. Importantly, we also ﬁnd cancer stem/ini-
tiating cells have short telomeres (compared to normal stem cells
which have relatively longer telomeres). The short telomeres in
cancer stem cells may reﬂect the multistep nature of cancer initia-
tion and progression. The immediate implications of this new tu-
mor growth paradigm not only require a re-evaluation of how
tumors are initiated, but also on how tumors should be monitored
and treated.
2. Bypass of senescence and crisis to become a cancer initiating
cell
Human telomeres consist of repetitive TTAGGG DNA sequences
that associate with a series of telomere binding (shelterin) proteins
[1] believed to provide genomic stability by protecting the linear
chromosome ends from being recognized as DNA breaks needing
repair. The inability of the DNA replication machinery to copy
the extreme ends of chromosomes, often referred to as the end rep-
lication problem [2], is consistent with the observation that cells
can lose telomeres without initially affecting cell function. Thus, al-
most all normal human cells including stem cells of renewal tis-
sues show progressive telomere shortening with ongoing cell
division until a subset of telomeres reach a critically shortened
length and induce a DNA damage signal that is often referred to
as replicative senescence or cell aging [3]. Thus, telomeres not only
serve as chromosome ‘caps’ to protect chromosome ends from
being recognized as DNA damage, but also serve as a gauge forlsevier B.V. All rights reserved.
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ing enzyme that synthesizes DNA onto the ends of chromosomes,
helps to maintain the integrity of the genome in embryonic stem
cells and in proliferating progenitor cells derived from quiescent
normal stem cells. Telomerase is silent in the vast majority of hu-
man tissues and is only expressed in a small number of normal cell
types such as dividing male germ-line spermatocytes and a subset
of proliferating somatic adult progenitor cells [4].
In 1991 we proposed a connection between telomeres, telome-
rase, aging and cancer [5]. The hypothesis put forth was that most
normal human cells lack telomerase activity and their telomeres
shorten with each cell division, until they enter replicative senes-
cence (Fig. 1). Cells that lose critical cell cycle checkpoint functions
escape this initial growth arrest (replicative senescence) and con-
tinue to divide (called extended lifespan by virologists who ﬁrst
identiﬁed that one of the important function of DNA tumor viruses
is to bypass senescence). Cells that bypass senescence eventually
enter a second growth arrest state (crisis) when many shortened
chromosome ends fuse, leading to chromosome bridge-breakage-
fusion cycles almost universally leading to apoptosis (Fig. 1). In hu-
man cells these two mechanisms to restrict cell growth (senes-
cence and crisis) are at least initially potent anticancer protection
mechanisms [6]. Most human cells remain in this crisis period with
cell growth being balanced by cell death until a rare cell acquires a
mechanism, such as telomerase expression, that can maintain or
lengthen telomeres [5,6]. This rare cell that can maintain telomeres
is then able to grow continuously (i.e. becomes immortal) and this
is generally believed to be a critical step in cancer progression [7].
Cells that have escaped crisis generally have two deﬁning hall-
marks, telomere stability and reactivation of telomerase [8,9]. This
suggests that the cancer stem (initiating) cell was likely to initially
have very short telomeres and recent evidence supports this idea
[10,11]. In these studies cancer cells with stem-like markers have
similar or shorter telomeres compared to the bulk of the tumorFig. 1. The M1 and M2 model of senescence and crisis. All normal human somatic cells h
proliferative (transit amplifying) adult stem cells. When a few telomeres in a cell reach a
that the shortened telomeres is being sensed as uncapped or broken DNA. In cells th
checkpoint genes (e.g. TP53 and/or pRB), cells ignore the ongoing DNA damage signal
extended lifespan period, end associations occur eventually leading to breakage-fusion-
almost universally occurs. However, in a rare human cell (based on ﬂuctuation analyses c
cell has two characteristics, expression of telomerase and stabilization of telomeres.[10,11]. There may thus either be an advantage and mechanism
to maintain subsets of cancer cells at very short telomere lengths
or the length varies with differentiation state of the tumor cells.
When telomerase is upregulated or reactivated in cells escaping
crisis many outcomes are possible. For example, there can be too
little telomerase expressed and these cells may not be able to di-
vide long-term and they are unlikely to become robust cancer cells.
If telomerase is made in excess then telomeres would be predicted
to grow rapidly leading to long telomeres, but this is only rarely
observed (less than 10% of primary cancers). Thus, there may be
no selective advantage for cancer cells having more telomerase
than is needed to maintain telomeres longer than that which pro-
vides protection against DNA-damage signaling/end-fusion. What
is observed is that the vast majority of human cancer cells have
telomeres generally the same or shorter than adjacent normal
tissues.
It is believed that greatly shortened telomeres in initiated but
still preneoplastic cells (while initially a potent anti-cancer protec-
tion mechanism) may also promote genomic instability and lead to
the development of advanced disease. It is widely accepted that ge-
netic instability drives malignant transformation. With only a few
cellular alterations, the DNA damage signals from telomere short-
ening (telomere uncapping) would be predicted to be a very potent
tumor suppressor pathway, since the ‘‘damage” could not be re-
paired in the absence of telomerase. Thus, replicative senescence
is likely to initially stop cells from proliferating and progressing
to cancer. This would certainly have an advantage in large long-
lived species such as humans but may be less important in short-
lived animals (such as mice). Proof that telomeres shortening and
cellular aging are causally and not just correlatively related was
provided in 1998 when Bodnar and co-workers [12] showed that
introduction of telomerase into normal telomerase silent cells
was sufﬁcient to bypass senescence, activate telomerase activity,
and lead to cell immortalization. It was further shown that ectopicave progressive shortening of telomeres with each cell division. This is also true in
shortened state, a DNA damage signal is initiated. This DNA damage signal indicates
at have bypassed the M1 senescent state by inactivation of important cell cycle
and continue to divide until many telomeres are critically shortened. During this
bridge cycles resulting in M2 or a state of crisis. During crisis apoptotic cell death
alculated to be about one in ten million cells) an immortalization event occurs. This
J.W. Shay, W.E. Wright / FEBS Letters 584 (2010) 3819–3825 3821expression of telomerase (TERT) in pre-senescent cells or in cells
between senescence and crisis could be immortalized with ectopic
introduction of TERT, demonstrating that telomeres are mechanis-
tically important in both senescence and crisis. In the absence of
intact critical check point pathways, genomic instability occurs
when telomeres are short, leading to end-to-end fusions, anaphase
bridges, the development of aneuploidy, and eventually to telome-
rase reactivation. One possibility is that the re-expression or up-
regulation of telomerase in cancer reduces the ongoing chromo-
somal instability that occurs in cells in crisis to a level compatible
with both viability and sufﬁcient instability to generate mutational
evolution of the malignancy. In summary telomere shortening may
be a common underlying cause of chromosomal rearrangements in
cancer.
3. Telomerase in stem cells
Normal tissue stem cells reside in microenvironmental niches
that are tissues/organ speciﬁc. Stem cells are negative for differen-
tiation markers, are not actively cycling in vivo, and generally form
large self-renewing colonies in vitro. Thus, there are many differ-
ences between normal stem cells in vivo and in vitro. The function
of stem cells appears to change with increased age and this may be
due in part to progressive telomere shortening. Stem cells also
show progressive shortening of telomeres with increased age,
while embryonic stem cells appear to fully maintain telomeres.
This is believed to be due to fully active telomerase in embryonic
stem cells that does not occur in stem cells of renewal tissues
(Fig. 2). Thus, while proliferative descendents of normal stem cells
have detectable telomerase activity, this activity is rarely sufﬁcient
to fully maintain telomere length (Fig. 2). Very little is known
about the regulation of telomerase in proliferative stem cells. Thus,
a major difference between normal tissue stem cells and cancer
cells is that in the latter but not the former, stable telomere length
are maintained. Normal tissue stem cells show progressive telo-
mere shortening with increased age and telomerase is carefully
regulated so that it is not continuously expressed. Thus, normal tis-
sue stem cells are telomerase competent but mostly silent, while
cancer cells are almost universally telomerase expressing. There
are no apriori reasons to assume that subsets of cancer cells (e.g.Germ cells ?
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Fig. 2. Changes in telomere length in germline cells, normal stem cells and
preneoplastic somatic cells. Telomeres progressively shortening in normal stem and
preneoplastic cells but not in proliferating male germline spermatocytes. When
telomeres are very short in preneoplastic cells, a rare cell stabilizes its telomeres by
upregulating or reactivating telomerase. This cell is likely to initially have very short
telomeres and telomerase may be a mechanism to reduce the ongoing genomic
instability that occurs when cells are in crisis at the time of immortalization. Thus,
the bulk of tumor cells including cancer stem cells have much shorter telomeres
compared to germline or normal stem cells. Robust telomerase inhibitors currently
in clinical trials are likely to induce apoptosis in cancer cells before adversely
affecting normal stem cell functions.cancer stem cells) would maintain their telomeres differently from
the bulk of the tumor, even though there are frequent comparisons
made between normal stem cells and cancer stem cells as if cancer
stem cells are simply derivatives of normal stem cells. This has led
to many misconceptions that persist in the general scientiﬁc
thought collective. Many of these comparisons are based on very
marginal data and will be discussed further. Importantly, cancer
cells expressing telomerase and forced to differentiate or to be-
come quiescent, either undergo apoptosis or down regulate telo-
merase [13] suggesting that part of becoming a cancer cell may
be the inability to efﬁciently undergo quiescence as do normal tis-
sue stem cells. Cancer cells may lack the cell cycle checkpoint
activities that allow them to completely growth arrest or there
may not be a cancer speciﬁc niche as occurs in normal stem cells
to allow cancer stem cells to become completely quiescent.
4. Background review of cancer stem cells
While the term ‘‘cancer stem cells” is still controversial, the
general consensus is that these cells must have potent tumor initi-
ation, self-renewal and differentiation capacity [14]. The evidence
for this is that it is difﬁcult to establish tumor cell lines even from
metastatic lesions. It generally takes hundreds of thousands (if not
millions) of established cancer cells to make a tumor in immuno-
suppressed mice and tumors that are initially clonal rapidly be-
come heterogeneous. Thus it is believed that the vast majority of
tumors do not have the characteristics of a cancer stem cell. One
of the main concerns about the cancer stem cell hypothesis is that
virtually all the work has involved transplanting human cancer
cells into a variety of different types of immunodeﬁcient mice.
Thus, the experiments supporting the cancer stem cell hypothesis
may not accurately reﬂect what happens during cancer initiation
and progression in humans. In addition, the idea that only a very
rare cell can initiate tumor formation has recently been challenged.
In one study, approximately 25% of single melanoma cells from
unselected melanoma cells isolated directly from patients were
able to make tumors in NOD/SCID/interleukin-2 receptor gamma
chain null mice [15]. If cancer stem cells are very rare as the
hypothesis suggests, it is hard to explain how a large fraction of
even single cells can reproducibly make tumors.
Even with these caveats, the tumor initiation aspect of cancer
stem cells refers to the capacity of these cells to form tumors in
immunocompromised mice using very small numbers of cells.
Self-renewal capacity is tested by serial transplantation experi-
ments, where re-isolated cancer stem cells can be transplanted in
secondary and tertiary recipients. The differentiation ability of
these cells does not refer to multilineage differentiation but rather
to the capacity of the resulting tumors to be a phenocopy of the
original tumor. An important characteristic of cancer stem cells is
their ability to survive various therapies by activating anti-apopto-
tic pathways, increasing activity of membrane transporters and
high DNA repair capacity [16,17]. The currently accepted deﬁnition
of cancer stem cells does not imply the cell type from which these
cells originated and thus the term the term tumor-initiating cells
may be more appropriate. There are still many outstanding ques-
tions, such as when do cancer stem cells arise, are they ever com-
pletely quiescent, is there a cancer stem cell niche, and are cancer
stem cells derived from normal stem cells or can transit amplifying
cancer progenitor cells also revert to cancer stem cells?5. Review of telomerase in cancer stem cells
Embryonic stem cells derived early in embryogenesis, are be-
lieved to proliferate by equal division where the two daughter cells
produced by the division share the same stem cell characteristics.
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by unequal division where the two daughter cells differ in their
characteristics such than one remains a stem cell and the other be-
comes a progenitor or transit amplifying cell. There is robust
experimental evidence that progenitor or transit amplifying nor-
mal cells express high levels of telomerase while the remaining
daughter stem cell rapidly becomes quiescent (e.g. not dividing
or very slowly dividing) and does not express telomerase. How
does this asymmetric cell division occur? What regulates symmet-
ric cell division in embryonic stem cells but asymmetric cell divi-
sion in normal tissue stem cells? What regulates telomerase
activity in quiescent stem cells versus proliferating transit amplify-
ing cells? While technological advances have made it possible to
isolate stem and progenitor cells and there is a beginning descrip-
tion of the molecular characteristic of these various cell types,
there is still much we do not know. Clearly the progenitor cells
can undergo many divisions to eventually differentiate into the
functional cells of the speciﬁc tissue but these are almost univer-
sally ‘‘end” cells that are eventually lost from the tissue after com-
pleting their physiological functions. In some tissues there are
many levels of transit amplifying cells while in others there are
not. The mass of a tissue is maintained by the balance between dif-
ferentiated cell death and production of new transit amplifying
cells. Some tissues turn over rapidly such as in the gastrointestinal
tract and thus there is a high number of transit amplifying cells. In
the brain there is almost no cell turnover and interestingly, the
telomeres of neuronal cells do not change with increased age.
The terminally differentiated cells of the brain and mature differ-
entiated gastrointestinal cells also do not express telomerase
activity.
6. Evidence for short telomeres in cancer stem cells
While there are many physical and cell surface markers that
have been used to identify cancer initiating/stem cells none are
universal and the biomarkers vary depending on the tissue of ori-
gin of the cancer. For example, in brain tumors, there is contro-
versy over whether a single cell marker (such as CD133/Prominin
1) can identify the tumor-initiating population [14,16,17]. How-
ever, there is general agreement that brain tumors cells which
can be propagated in vitro as non-adherent neurospheres and pro-
duce intracranial tumors retain the genotype and phenotype of the
patient’s original tumor [18,19]. In a recent study Marian et al. [10]
demonstrated that CD133+ primary glioblastoma mutiformi (GBM)
cells could form neurospheres, were capable of make orthotopic
tumors at low seeding numbers, and could differentiate into three
different brain lineages. Neurospheres generated in vitro by pri-
mary GBM cells are enriched in stem/progenitor cells. This tech-
nique is based on the unique property of stem/progenitor cells to
survive and grow in serum-free suspension, while more differenti-
ated cells undergo anoikis and die in these conditions. Thus, these
cells, by well accepted criteria, have the characteristics of cancer
stem or initiating cells. The studies found that these putative gli-
oma stem cells expressed telomerase. More importantly, not only
were the telomere lengths of tumors shorter than normal brain
telomeres but that the telomere length of GBM tumor-initiating
cells expressing CD133 had even shorter telomeres (3.5 kb), than
the bulk of tumor cells. Thus, the average telomere lengths of GBM
putative tumor stem cells were approximately three times shorter
compared to normal human brain cells.
In another study examining the dye Hoechst 33342 dye exclu-
sion marker called SP (side population), Ponti et al. [20] demon-
strated that primary breast carcinoma-derived cultures were
capable of self-renewal, extensive proliferation as clonal non-
adherent spherical clusters, and could differentiate along differentmammary epithelial lineages (ductal and myoepithelial). As with
the GBM study, breast cancer-initiating cells in this study dis-
played a similar extent of telomerase activity as the bulk of the tu-
mors. In addition, the telomere length was similar to adjacent non-
cancerous tissue telomere length.
Using speciﬁc surface markers (CD44, integrin a2b1 and CD133),
Hoechst 33342 dye exclusion, and holoclone formation, tumor ini-
tiating cells were isolated [11] from a panel of prostate cancer cell
lines (DU145, C4-2 and LNCaP). Tumor cells with putative stem cell
markers [21–25] were isolated from these cell lines and all had
signiﬁcant telomerase activity and the telomeres were of similar
average length as the telomeres of the main population of cells.
Holoclones (tightly packed round colonies of cells with distinct
morphology) were also able to re-initiate tumor growth [23] and
these had both telomerase and short telomeres [11]. Finally in a
series of studies involving multiple myeloma both CD138+ plasma
cells and CD138 precursors were observed to express telomerase
activity. These investigators demonstrated that the malignant
CD138+ plasma cells in multiple myeloma had limited replicative
potential while the clonogenic cancer stem cells resemble normal
memory B cells (CD138CD19+CD27+) [26]. Using a telomerase
inhibitor currently in clinical trials (Imetelstat or GRN163L), they
found a marked reduction of telomerase activity in both the
CD138+ and CD138 cells and more importantly that Imetelstat
inhibited the in vitro clonogenic growth of CD138 putative cancer
stem cells isolated from the bone marrow aspirates of myeloma
patients [W. Matsui et al., ASH, 2006]. These ﬁndings provide
added support that multiple myeloma stem cells are not quiescent
since they express telomerase activity and also that they are likely
to have short telomeres since the stem cells lost their clonogenic
potential rapidly when telomerase was inhibited. Finally, recent
results suggest that the majority of leukemia stem cells are not
quiescent and may have features of aberrantly self-renewing com-
mitted progenitors or precursors, as opposed to quiescent adult tis-
sue stem cells [27].
Investigating the telomere length of putative cancer stem cells
is important, since it is theoretically possible for these cells to have
longer telomeres, similar to normal stem cells. However, since
these cells had to bypass senescence and crisis, it is more logical
to assume that the cancer cell that ﬁrst became immortal by upreg-
ulating telomerase would have had short telomeres. For example,
in most cases of preneoplasia it has been shown that cells have
very short telomeres [28–30]. In prostate cancer for example, telo-
mere shortening is detected in low grade prostatic intraepithelial
neoplasia (PIN) lesions, and is restricted to the luminal compart-
ment [28–30]. This indicates that the tumor initiating cells are
likely to originate from a subset of transient amplifying cells which
may have critically shortened telomeres perhaps due to chronic
inﬂammation. While speculative, this not only leads to short telo-
meres but also genomic instability and eventually re-activation of
telomerase. That 60% of high grade PIN lesions express telomerase
activity is evidence in support of this scenario [28].
7. Self-renewal in cancer stem cells versus bulk tumor cells
The concept of self-renewal has signiﬁcant meaning when ap-
plied to normal stem cells, where the evidence for a unidirectional
differentiation (from progenitor to transient amplifying or other
cell) is strong and where distinct properties of the cells exist. How-
ever, there are a variety of reasons why one needs to be cautious in
applying the concept of self-renewal to cancer stem cells. On the
one hand, a telomerase-expressing normal ﬁbroblast is immortal
and thus clearly capable of self-renewal, so self-renewal cannot
be an exclusive property of cancer stem cells. In addition, there
are many examples where investigators have studied cancer cell
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stem cells. There are at least three situations in which a cell line
could stably maintain this characteristic. Stable populations would
exist if the stem cells grew faster than the bulk of the cells but con-
stantly generated more differentiated progeny, in which case stem
cell numbers could be maintained. This situation certainly conﬂicts
with a general assumption that cancer stem cells would be quies-
cent or grow less rapidly than the bulk of tumor cells, but is consis-
tent with self-renewal. The growth rate of the cancer stem cells in
culture could be identical to that of the bulk tumor cells, which is
possible. Finally, the differentiation characteristics of tumor cells
could be ﬂuid, where progeny of more differentiated cells could as-
sume more stem-like characters and vice versa. Clones of cells
expressing cancer stem-cell markers can clearly give rise to popu-
lations dominated by ‘‘bulk population tumor cells”, and clones of
cells that seem to lack stem cell markers give rise to populations in
which cells expressing cancer stem cell markers can be found. It is
unclear what self-renewal would mean if cells can transition back
and forth between these states. Given the multiple genetic and epi-
genetic changes associated with malignancy it would not be sur-
prising that one might need a much more ﬂexible interpretation
of stem cells in the context of tumors.
8. Do cancer initiating/stem cells have different DNA strands?
Similar to normal stem cells is it reasonable to speculate that in
order for the cancer initiating/stem cell to retain a more stabilized
genome compared to the bulk of the tumor that they have to retain
a mechanism to minimize ongoing DNA damage? The cancer stem
cell model proposes that tumor progression, metastasis and re-
lapse after therapy may be driven by a rare subset of tumor cells
that possess the capacity to self-renew while the bulk of the tumor
does not (Fig. 3). As already described, there is a robust published
literature indicating that preneoplastic cells have very short telo-
meres [28–30]. Thus progressive telomere shortening results inN l li t dew y rep ca e
DNA t d s ran
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Fig. 3. Hypothetical model for retention of template immortal DNA strand in cancer stem
it is possible that the cancer initiating/stem cell have engaged a mechanism to retain
centromeric DNA as well as at speciﬁc genomic sites, speciﬁc cancer cells (which are no
retain the template immortal strand and the parental centriole in the cancer stem cell w
more differentiated cells. While this would help explain the rare nature of cancer stemchromosome end associations, fusions, anaphase bridges and
breakages with each cell cycle, and may lead to global genomic
instability that is characteristic of most cancer cells. If telomerase
upregulation or reactivation is a means to slow down or stabilize
the ongoing genomic instability changes, this could help provide
a possible explanation for why putative cancer stem cells have
short telomeres. It also suggests that robust telomerase inhibition
could be an effective anti-cancer therapeutic approach that would
target both the bulk of the cancer cells as well as the dividing can-
cer stem cells.
In normal cells, during anaphase separation of chromosomes, it
is believed there is either random segregation of DNA strands or
asymmetric segregation of DNA strands to daughter cells. That
individual chromosomes can be partitioned non-randomly has
been controversial and difﬁcult to prove. While random segrega-
tion would not require the engagement of a new regulatory mech-
anism, asymmetric segregation of DNA strands would require such
a mechanism but it would potentially have a selective advantage to
minimize the replication errors if the parental ‘‘immortal” strand
was segregated to the stem cells. In this hypothesis, the stem cell
keeps the template DNA strand after a round of DNA synthesis,
while the progenitor cells inherit the newly replicated daughter
strands. Thus the stem cells that inherit the parental template
strand might have fewer errors, while the new replicated strands
with possible replication errors would eventually be discarded
when the terminally differentiated cells are eliminated from the
body. Even though there is limited data to support that there are
fewer replication errors in stem cells compared to more differenti-
ated cells, it does pose the question if this same model can be
extrapolated to cancer stem cells (Fig. 3)? Approximately 35 years
ago a mechanism to avoid replication mediated mutations was
proposed by John Cairns [31] and was termed the immortal strand
hypothesis. Others had clearly considered non-random segregation
of chromatids at mitosis [32] but Cairns was the ﬁrst to propose
this as a mechanism involved in the origin of cancer cells [31,33].Cancer stem cell
Cancer 
dettimmoc
cells
itt d/diff ti t d ller comm e eren a e  ce s
cells. Similarly to a proposed mechanism that may exist in certain adult stem cells,
speciﬁc characteristics of stem cells. Perhaps due to distinct epigenetic marks at
t quiescent, express telomerase, and have shortened telomeres), may preferentially
hile the newly replicated DNA strands may segregate with the cancer committed or
cells, currently there is a lack of experimental support.
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may be mostly quiescent or slow dividing and thus much rarer
than the transit amplifying or differentiated cells. Thus, the cancer
stem cell may retain the template immortal strand while the can-
cer committed or more differentiated cancer cells may contain the
newly replicated DNA strands (Fig. 3). While currently there is no
experimental evidence to support this concept in cancer cells,
there are recurring reports that such a mechanism may occur in
some normal stem cells [34–40].
An alternate hypothesis [41] is that, following DNA replication,
sister chromatids in tissue-speciﬁc stem or progenitor cells carry
distinct epigenetic marks at centromeric DNA as well as at speciﬁc
genomic sites. This could be regulated by a speciﬁc niche or micro-
environmental stimulus to protect the cells from replication errors.
There is some evidence that epigenetic differences between sister
chromatid centromeres may be required to direct non-random seg-
regation of sister chromatids during mitosis, and thus epigenetic
differences at certain genes could regulate the expression of those
genes following mitosis. According to this hypothesis, selective
retention of chromatids with ‘‘active” stem cell genes may result
in maintenance of self-renewal properties. It also predicts that
there will be loss of stem cell properties in the cell that inherits
the opposite ‘‘silent” sister chromatids. Either the immortal strand
or the silent sister chromatids hypothesis for normal stem cells
could also be applied to cancer cells. Both of these mechanisms
may be dependent on cell polarity and parental centriole retention.
9. Conclusions and perspectives
Clearly long-lived animals protect the steady state of their tissues
by continuous replacement of the cells that regularly differentiate
and die. An adult human contains approximately 1012 rapidlymulti-
plying cells. During a typical30 000 day lifespan (80 years), each
person makes and discards an enormous number of cells from the
bone marrow, skin, and gastrointestinal track each day [42]. In the
absence of a mechanism to deal with spontaneous rates of sporadic
mutations, cancer in humanswouldbe a lotmoreprominent andap-
pear earlier in life than already occurs. Mechanisms to minimize
genomic damage are essential for large long-lived species. While
much remains to be discovered, organ systems in large long-lived
species have evolved mechanisms that dramatically slow the rate
of accumulation of replication errors. In this minireview we have
presented some evidence that cancer stem/initiating cells have
many differences from normal stem cells and presented a variety
of hypotheses for how thismay occur. Importantly, we have learned
that there are differences in telomere lengths and telomerase activ-
ity between normal and cancer stem cells. This knowledgemay help
us identify unique vulnerabilities that can be targeted as speciﬁc
cancer therapeutic approaches while avoiding targeting our much
needednormal stemcells. How subsets of tumor cells have co-opted
the capacity for self-renewal and differentiation is an active area of
research. New knowledge in this ﬁeld is beginning to build a ratio-
nale for targeting pathways of aberrant self-renewal in the treat-
ment of many cancer types.
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